Fig. 1.

Flowchart of the study; 667 female patients underwent our FP program before a gonadotoxic treatment from January 2009 to October 2017. Forty patients cured from cancer asked for the use of oocytes or embryos cryopreserved in this context. We divided this population into four groups according to FP technique performed: oocyte or zygote cryopreservation after COS (OO-COS and ZYG-COS) or after IVM (OO-IVM and ZYG-IVM). COS, controlled ovarian stimulation; IVM, in vitro maturation; OO-COS, oocytes cryopreserved after controlled ovarian stimulation; OO-IVM, oocytes cryopreserved after in vitro maturation; ZYG-COS, zygotes cryopreserved after controlled ovarian stimulation; ZYG-IVM, zygotes cryopreserved after in vitro maturation